Anti-heparin/PF4 complexes by ELISA in patients with disseminated intravascular coagulation

Pathophysiology of Haemostasis and Thrombosis

Volumn 36, Issue 6, 2007, Pages 305-310

  Matsuo, Takefumi ^a   Matsuo, Miyako ^b   Sugimoto, Takaki ^a   Wanaka, Keiko ^c  

^a HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

^b HYOGO CANCER CENTER   (Japan)

^c Kobe Research Projects on Thrombosis and Haemostasis   (Japan)

Author keywords

Anti heparin PF4 complexes; Disseminated intravascular coagulation; Heparin induced thrombocytopenia

Indexed keywords

ALPHA 2 ANTIPLASMIN; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY;

ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANTIBODY TITER; ARTICLE; BLEEDING; BLOOD CLOTTING; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HEMATOLOGIC MALIGNANCY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNOPATHOLOGY; INFECTION; ISCHEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OPTICAL DENSITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TISSUE INJURY; UREMIA; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; ANTITHROMBIN III; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD COAGULATION; DISSEMINATED INTRAVASCULAR COAGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIN; FIBRINOLYSIS; HEPARIN; HUMANS; KIDNEY FAILURE; MALE; PEPTIDE HYDROLASES; PLATELET COUNT; PLATELET FACTOR 4; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 77952407188     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000296281     Document Type: Article

References (17)

1. Bell WR, Royall RM: Heparin-associated thrombocytopenia: a comparison of three heparin preparation. N Engl J Med 1980;303:902-907.
2. Zalcberg JR, McGrath K, Dauer R, Wiley JS: Heparin-induced thrombocytopenia with associated disseminated intravascular coagulation. Br J Haematol 1983;54:655-660.
3. Castaman G, Ruggeri M, Girardell R, Rodeghiero F: An unusually prolonged case of heparin-induced thrombocytopenia and disseminated intravascular coagulation. Haematologica 1992;77:174-176.
4. Mukundan S, Zeigler ZR: Direct antithrombin agents ameliorate disseminated intra-vascular coagulation in suspected heparin-induced thrombocytopenia thrombosis syndrome. Clin Appl Thromb Hemost 2002;8:287-289.
5. Bakhitiari K, Meijers JCM, de Jonge E, Levi M: Prospecive validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004;32:2416-2421.
6. Hayakawa M, Gando S, Hoshino H: A prospective comparative study of three sets of criteria for disseminated intravascular coagulation: ISTH vs. Japanese criteria. Clin Appl Thromb Hemost 2007;13:65-72. (Pubitemid 44905284)
7. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG: Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005;146:341-346.
8. Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA: Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004;2:2133-2137.
9. Warkentin TE, Shenppard JI, Moore JC, Sigouin CS, Kelton JG: Quantitative interpretation of optical density measurement using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008;6:1304-1312.
10. Weiss BM, Shumway NM, Howard RS, Ketchum LK, Reid TJ: Optical density values correlate with the clinical probability of heparin induced thrombocytopenia. J Thromb Thrombolysis 2008;26:243-247.
11. Warkentin TE, Heddle NM: Laboratory diagnosis of immune heparin-induced thrombocy topenia. Curr Hematol Rep 2003;2:148-157.
12. Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A: Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006;76:420-426.
13. ten Cate H: Thrombocytopenia: one of the markers of disseminated intravascular coagulation. Pathophysiol Haemost Thromb 2003-2004;33:413-416.
14. Warkentin TE: Heparin-induced thrombocytopenia, diagnosis and management. Circulation 2004;110:e454-e458.
15. Oliveria GBF, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, Rodgers JO, Steinhubl SR, Tapson VF, Ohman EM, Granger CB: Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008;168:94-102.
16. Kario K, Matsuo T, Kodama K, Matsuo M, Yamamoto K, Kobayashi H: Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation: assessment by the thrombin-antithrombin-III complex/plasmin-alpha- 2-antiplasmin complex ratio. Haemostasis 1992;22:179-186.
17. Chilver-Stainer LC, Lämmle B, Alberio L: Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thromb Haemost 2004;91:276-282.